No press releases found.
Court Narrows Moderna Defenses in Arbutus Patent Dispute
TipRanks (Fri, 20-Feb 4:46 PM ET)
Moderna dealt blows in ongoing patent dispute with Arbutus
Seeking Alpha News (Wed, 18-Feb 9:42 AM ET)
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Arbutus Biopharma trades on the NASDAQ stock market under the symbol ABUS.
As of February 23, 2026, ABUS stock price climbed to $4.39 with 1,055,959 million shares trading.
ABUS has a beta of 0.50, meaning it tends to be less sensitive to market movements. ABUS has a correlation of 0.05 to the broad based SPY ETF.
ABUS has a market cap of $844.30 million. This is considered a Small Cap stock.
Last quarter Arbutus Biopharma reported $529,000 in Revenue and -$.04 earnings per share. This fell short of revenue expectation by $-781,250 and met earnings estimates .
In the last 3 years, ABUS traded as high as $5.10 and as low as $1.69.
The top ETF exchange traded funds that ABUS belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.
ABUS has outperformed the market in the last year with a price return of +27.6% while the SPY ETF gained +13.0%. However, in the short term, ABUS had mixed performance relative to the market. It has underperformed in the last 3 months, returning +4.5% vs +4.9% return in SPY. But in the last 2 weeks, ABUS shares have fared better than the market returning +14.3% compared to SPY -1.2%.
ABUS support price is $4.10 and resistance is $4.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABUS shares will trade within this expected range on the day.
